Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 15 studies | 34% ± 16% | |
conventional dendritic cell | 14 studies | 36% ± 18% | |
non-classical monocyte | 9 studies | 30% ± 13% | |
macrophage | 9 studies | 26% ± 8% | |
mast cell | 9 studies | 25% ± 16% | |
monocyte | 8 studies | 21% ± 6% | |
dendritic cell | 7 studies | 37% ± 15% | |
myeloid cell | 4 studies | 33% ± 15% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 27% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 721.83 | 578 / 578 | 74% | 2.36 | 856 / 1155 |
breast | 92% | 211.94 | 421 / 459 | 81% | 2.07 | 905 / 1118 |
kidney | 58% | 119.81 | 52 / 89 | 79% | 2.81 | 710 / 901 |
bladder | 95% | 258.90 | 20 / 21 | 37% | 0.99 | 186 / 504 |
intestine | 96% | 217.70 | 927 / 966 | 36% | 0.71 | 188 / 527 |
thymus | 63% | 84.14 | 411 / 653 | 65% | 1.47 | 392 / 605 |
skin | 58% | 78.95 | 1048 / 1809 | 66% | 2.86 | 313 / 472 |
brain | 36% | 58.19 | 963 / 2642 | 85% | 3.58 | 600 / 705 |
uterus | 81% | 114.68 | 137 / 170 | 41% | 0.89 | 186 / 459 |
adrenal gland | 96% | 273.03 | 247 / 258 | 25% | 0.55 | 57 / 230 |
stomach | 71% | 120.48 | 254 / 359 | 46% | 1.14 | 132 / 286 |
ovary | 51% | 65.52 | 91 / 180 | 63% | 1.54 | 271 / 430 |
prostate | 84% | 144.63 | 207 / 245 | 24% | 0.34 | 121 / 502 |
pancreas | 34% | 43.48 | 110 / 328 | 70% | 1.79 | 124 / 178 |
esophagus | 76% | 142.08 | 1103 / 1445 | 24% | 0.43 | 44 / 183 |
spleen | 100% | 2005.57 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 462.86 | 1198 / 1204 | 0% | 0 | 0 / 0 |
liver | 60% | 94.24 | 135 / 226 | 37% | 0.77 | 150 / 406 |
peripheral blood | 95% | 1389.16 | 880 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 5.81 | 27 / 29 |
blood vessel | 82% | 204.23 | 1096 / 1335 | 0% | 0 | 0 / 0 |
heart | 68% | 104.78 | 587 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 58% | 1.26 | 26 / 45 |
muscle | 15% | 13.11 | 117 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 11% | 0.18 | 9 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0150102 | Biological process | negative regulation of monocyte activation |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0007165 | Biological process | signal transduction |
GO_0007155 | Biological process | cell adhesion |
GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
GO_0007267 | Biological process | cell-cell signaling |
GO_0050714 | Biological process | positive regulation of protein secretion |
GO_0032717 | Biological process | negative regulation of interleukin-8 production |
GO_0002765 | Biological process | immune response-inhibiting signal transduction |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0098609 | Biological process | cell-cell adhesion |
GO_0038094 | Biological process | Fc-gamma receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005777 | Cellular component | peroxisome |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0033691 | Molecular function | sialic acid binding |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0008160 | Molecular function | protein tyrosine phosphatase activator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CD33 |
Protein name | Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33) CD33 molecule (cDNA FLJ50122, highly similar to Myeloid cell surface antigen CD33) CD33 molecule transcript variant CD33 antigen (Gp67) |
Synonyms | hCG_91950 SIGLEC3 |
Description | FUNCTION: Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state . Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans . Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK . These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 . In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules . One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K . . |
Accessions | ENST00000391796.7 [P20138-2] Q546G0 ENST00000436584.6 ENST00000262262.5 [P20138-1] ENST00000421133.6 [P20138-3] A0A173G4N9 P20138 B4DF51 |